Reports Q4 revenue $2.59M, consensus $130,000. Michael Rowe, CEO, commented, “During the fourth quarter and subsequent period, we continued to execute on our corporate strategy that we initiated just a few quarters ago. FDA approval of clobetasol propionate ophthalmic suspension 0.05% gives us access to a large-market indication that is complementary to Mydcombi and allows us to add additional value to eye doctors using our existing field sales force. Additionally, our recent decision to reacquire the development and commercialization rights to MicroPine expands our pipeline with a potential blockbuster drug, if approved. With the CHAPERONE study in our hands, we plan to engage with FDA later this year to explore ways to expedite its development.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EYEN:
- Options Volatility and Implied Earnings Moves Today, March 18, 2024
- Eyenovia (EYEN) Q4 Earnings Cheat Sheet
- NovaBay, Eyenovia to co-promote prescription ophthalmic products
- NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
- Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th